From Vision To Legacy

Article

Sharsheret is a national not-for-profit organization supporting young Jewish women and their families facing breast cancer and ovarian cancer.

Sharsheret is a national not-for-profit organization supporting young Jewish women and their families facing breast cancer and ovarian cancer. Our mission is to offer a community of support to women, of all Jewish backgrounds, diagnosed with breast cancer or at increased genetic risk, by fostering culturally-relevant individualized connections with networks of peers, health professionals, and related resources.

Recent Videos
a woman sitting in front of a green wall with a white top and glasses
a woman with a white shirt and glasses sitting in front of a green wall.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
Pattie Jakel
Christine Wylie
Related Content
Amanda Brink, DNP, APRN, FNP-BC, AOCNP

Opinion: A Case of Self-Experimentation with Oncolytic Virus Therapy Highlights the Need for More Research

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
December 30th 2024
Article

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to available clinical trial opportunities.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Amanda Brink, DNP, APRN, FNP-BC, AOCNP

Opinion: Chromosomal Abnormalities in Healthy Breast Tissue May Be Early Indicators of Cancer Risk

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
December 23rd 2024
Article

Oncology nurses can educate patients on the implications of these findings

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

PARP inhibitor

Neoadjuvant Niraparib/Dostarlimab Combo May Yield pCRs in BRCS+, ER+/HER2- Breast Cancer

Ariana Pelosci
December 19th 2024
Article

Additional exploration may help fully realize the impact of combining immunologic approaches with PARP inhibition, says one expert.

circulating tumor DNA

Study Supports Role of ctDNA in Predicting Outcomes in HR+ Early Breast Cancer

Ashley Chan
December 17th 2024
Article

Baseline ctDNA presence was associated with larger tumor size and higher residual disease burden scores following neoadjuvant endocrine therapy in HR-positive, early breast cancer.